Core Viewpoint - Xinjiang Zhonghe announced the decision to exercise the early redemption of "Zhonghe Convertible Bonds" at the board meeting held on February 9, 2026, which will redeem all registered bonds at face value plus accrued interest [2] Group 1 - The company will hold its first temporary board meeting of the tenth session on February 9, 2026 [2] - The board approved the proposal for the early redemption of "Zhonghe Convertible Bonds" [2] - The redemption will occur at the price of the bond's face value plus the interest accrued up to the redemption registration date [2]

Core Viewpoint - The company is advancing its globalization strategy by establishing a research and development office in Boston, covering approximately 2,000 square meters, which has already begun generating revenue [2] Group 1: Global Expansion Strategy - The company aims to increase the proportion of overseas customer revenue to about 47% by 2025, with a positive year-on-year growth in new overseas orders [2] - The Boston laboratory will collaborate with domestic research centers to share resources and achieve differentiated development, focusing on meeting the growing demands of overseas clients [2] - The company is enhancing its laboratory capabilities and business team configurations in key overseas regions, including Europe and Asia-Pacific [2] Group 2: Business Development and Market Engagement - The company has established a business development (BD) team of over ten members overseas and plans to strengthen the BD team in Europe [2] - There will be improved communication and collaboration between the overseas BD teams and domestic research teams, along with the establishment of a customer information intelligence system [2] - The company intends to actively participate in international industry conferences and increase the frequency of research team outreach to expand its overseas market presence [2]

证券日报网讯 2月9日，国科天成在互动平台回答投资者提问时表示，关于公司研发情况及对外投资情 况，请以公司披露的公告为准。 （文章来源：证券日报） ...

Core Viewpoint - Meitu Company reported a significant increase in adjusted net profit for the fiscal year 2025, driven by rapid growth in revenue from its imaging and design products, particularly from the increase in global paid subscription users [2] Financial Performance - For the fiscal year 2025, adjusted net profit attributable to equity holders of the parent company is expected to grow by approximately 60% to 66% year-on-year [2] - In 2024, Meitu's total revenue reached 3.34 billion yuan, representing a year-on-year growth of 23.9%, with adjusted net profit of 586 million yuan, up 59.2% [2] Market Dynamics - The growth in paid subscription users is primarily driven by international markets, which are outpacing the growth in the domestic Chinese market [2] One-time Events Impact - According to International Financial Reporting Standards, the net profit attributable to equity holders of the parent company is expected to decline by no more than 30% compared to the previous year due to a high base effect from a one-time net gain of approximately 640 million yuan from cryptocurrency sales in 2024 and a one-time non-cash expense of about 512 million yuan from issuing convertible bonds to Alibaba in 2025 [2] - The company emphasized that these two items are one-time, non-operational events and do not reflect the core business performance [2] Upcoming Announcements - Meitu is scheduled to release its full-year results for 2025 on March 27 [2]

（文章来源：证券日报） 证券日报网讯 2月9日，东方电气发布公告称，公司高级副总裁王军、副总裁胡修奎、副总裁但军减持 计划已实施完毕，三人分别减持6200股、16200股、7500股，合计占公司总股本的0.00087%，减持价格 区间为24.18元/股至27.07元/股。 ...

从整个市场规模来看，高盛认为，AI为影像领域带来新机遇，预计2025至2030年全球AI图像和视频市 场规模将以44%的复合年增长率增长至390亿美元。其中，美图得益于生产力工具的推广、海外市场的 拓展、付费率的上升以及持续推出的新产品，预计2025年至2030年收入复合年增长率将达到29%。 高盛在报告中对美图不同业务和市场对收入的贡献也作出了预测。该行指出，美图的生产力工具业务正 加速发展，预计到2030年，生产力收入贡献将达到44%；与此同时，得益于在欧洲、东南亚等地区的扩 张，美图的海外月活将加速增长；因其产品组合向生产力工具的升级及海外市场拓展，海外市场变现加 速，付费率预计到2030年达11.3% 2月8日，高盛发布报告首次覆盖美图公司（以下简称"美图"），给予"买入"评级，12个月目标价16港 元。公开信息显示，这一目标价高于大摩、瑞银、美银等大行给出的目标均价。高盛称，看好AI影像 领域的高收入和美图在特定场景下满足用户需求的竞争优势，对其未来两年的预测比市场一致预期更 高。 针对近期市场关于大模型吞噬应用的讨论，高盛在报告中指出，尽管通用模型和工具能够降低AI的入 门门槛并减少用户的工作量， ...

Core Viewpoint - Jiuyuan Gene has submitted an IND application for its innovative drug JY54 injection, aimed at weight management for obese or overweight individuals, marking a significant advancement in the metabolic treatment field [2] Group 1: Product Development - JY54 injection is a long-acting insulin analog designed to manage weight, showcasing Jiuyuan Gene's commitment to innovation in metabolic diseases [2] - The product is a dual receptor agonist (DACRAs) that mimics natural insulin mechanisms, offering multiple actions such as inhibiting glucagon secretion, delaying gastric emptying, and reducing appetite [3] - Clinical pre-research indicates that JY54 injection has demonstrated excellent efficacy and safety, with significant potential for weight loss and metabolic improvement [6] Group 2: Market Positioning - The global obesity and metabolic disease prevalence is rising, making weight management therapies a highly active area for pharmaceutical innovation [3] - JY54 injection's mechanism is believed to have advantages over current GLP-1 drugs, potentially leading to better fat reduction while preserving muscle mass [3] - The product's unique molecular structure supports long-acting administration, enhancing patient compliance and laying the groundwork for future combination therapies with GLP-1 [5] Group 3: Strategic Direction - Jiuyuan Gene's pipeline includes both mature products and innovative therapies, creating a clear gradient layout that addresses current market needs while exploring future treatment advancements [6] - The combination of mature products and innovative pipelines is expected to build a resilient long-term development structure in the metabolic disease sector [6] - The acceptance of the IND application reflects Jiuyuan Gene's ongoing investment in innovative drug development and its ambition to enhance its global influence in the metabolic drug innovation field [6]

证券日报网讯 2月9日，海立股份在互动平台回答投资者提问时表示，公司在定期报告中披露对应期末 时点的股东信息。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article is that Jiuri New Materials has confirmed ongoing research and development in solid-state batteries through its affiliate, Plana Nano, but has not yet achieved mass production [2] - The company currently has no plans to integrate Plana Nano into the publicly listed company [2]

证券日报网讯 2月9日，东芯股份在互动平台回答投资者提问时表示，公司坚持稳定可靠的供应链体 系，与国内外多家知名晶圆代工厂和封测厂建立了互助、互利、互信的合作关系，构建了"本土深度、 全球广度"的供应链网络，目前产能供应稳定。 （文章来源：证券日报） ...